Ask AI
APP BsAb in MM

CE

APP Perspectives: Safe and Effective Use of Bispecific Antibodies in Multiple Myeloma

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: November 17, 2025

Expiration: May 16, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Talquetamab-tgvs [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2025. 
  2. Teclistamab-cqyv [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2025.
  3. Elranatamab-bcmm [prescribing information]. New York, NY: Pfizer Inc.; 2025.
  4. Linvoseltamab-gcp [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; 2025.
  5. Puttkammer JR, Barreto JN, Jensen CJ, et al. Outpatient management of bispecific related toxicities: an observational study of safety outcomes and resource utilization. JCO Oncol Pract. 2025;[Epub ahead of print].
  6. Scott SA, Roberts DL, Gupta VA, et al. Feasibility and safety of outpatient model for administration of bispecific antibodies: proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract. Clin Lymphoma Myeloma Leuk. 2025;25:656-660.
  7. Garfall AL, Banerjee R, Frenzel L, et al. A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma. Front Oncol. 2025;15:1630146.
  8. Borrello I. Can we change the disease biology of multiple myeloma? Leuk Res. 2012;3(Suppl 1):S3-S12.
  9. Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802-1824.
  10. Malard F, Neri P, Bahlis NJ, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10:45.
  11. Nooka AK, Kastritis E, Dimopoulos MA, Lonial S. Treatment options for relapsed and refractory multiple myeloma. Blood. 2015;125:3085-3099.
  12. Sonneveld P. Management of multiple myeloma in the relapsed/refractory patient. Hematology Am Soc Hematol Educ Program. 2017;2017(1):508-517.
  13. Bazarbachi AH, Al Hamed R, Malard F, Harousseau JL, Mohty M. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia. 2019;33(10):2343-2357.
  14. Ciltacabtagene autoleucel [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2025.
  15. Idecabtagene vicleucel [prescribing information]. Summit, NJ: Celgene Corporation, a Bristol-Myers Squibb Company; 2025.
  16. Barilà G, Rizzi R, Zambello R, et al. Drug conjugated and bispecific antibodies for multiple myeloma: improving immunotherapies off the shelf. Pharmaceuticals (Basel). 2021;14:40.
  17. van de Donk NWCJ, Chari A, Mateos MV. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies. Lancet Haematol. 2024;11:e693-e707.
  18. Garfall AL, Nooka AK, van de Donk N, et al. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2024;42:7540.
  19. Prince HM, Bahlis NJ, Rodríguez-Otero P, et al. MagnetisMM-3: long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma. Blood. 2024;144(Suppl 1):4738.
  20. Chari A, Touzeau C, Schinke C, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. Lancet Haematol. 2025;12:e269-e281.
  21. Bumma N, Richter J, Jagannath S, et al. Linvoseltamab for treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2024;42:2702-2712.
  22. Dima D, Davis JA, Ahmed N, et al. Safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma: a real-world experience. Transplant Cell Ther. 2024;30:308.e1-308.e13.
  23. Nooka AK, Lesokhin AM, Mohty M, et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies. J Clin Oncol. 2023;41:8008.
  24. Lee H, Neri P, Bahlis NJ. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms. Blood. 2024;143:1211-1217.
  25. Jakubowiak AJ, Anguille S, Karlin L, Chari A, et al. Updated results of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1/2 MonumenTAL-1 study. Blood. 2023;142(Suppl_1):3377.
  26. Dhakal B, Akhtar OS, Cowan AJ, et al. Talquetamab bridging: paving the way to B-cell maturation antigen (BCMA) CAR-T cell therapy in relapsed/refractory multiple myeloma (RRMM). Blood. 2024;144(Suppl 1):931.
  27. Dhakal B, Akhtar OS, Fandrei D, et al. Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T cell therapy. Blood. 2025;[Epub ahead of print].
  28. Fandrei D, Seiffert S, Rade M, et al. Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma. Blood Cancer Discov. 2025;6:38-54.
  29. Association of Cancer Care Centers. Successful integration of bispecific antibodies into community oncology practice: a blueprint for successful integration of bispecific antibodies. cdn.sanity.io/files/0vv8moc6/accc-cancer/6ff749df8c110fd1e994d9a405cde79817f68d6b.pdf. Accessed November 14, 2025.
  30. Rosenberg M, Scarpetti L, Morgan GJ, et al. Moving towards the delivery of outpatient T-cell engaging therapy for the management of multiple myeloma. Clin Lymphoma Myeloma Leuk. 2025;25:e709-e720. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: hematopoietic growth factors. v.1.2026. nccn.org. Accessed November 14, 2025.
  31. Scott SA, Marin EM, Maples KT, et al. Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience. Blood Cancer J. 2023;13:191.